Agarwal, Rishu <br/><br/>
Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials.  [electronic resource] 

 -  Leukemia & lymphoma  12 2018 
 - 2769-2781 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>1029-2403 
<br/><br/><label>Standard No.: </label>10.1080/10428194.2018.1457148  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenine--analogs & derivatives<br/>Agammaglobulinaemia Tyrosine Kinase--antagonists & inhibitors<br/>Bridged Bicyclo Compounds, Heterocyclic--pharmacology<br/>Clinical Trials as Topic<br/>Drug Resistance, Neoplasm--genetics<br/>Humans<br/>Lymphoma, Mantle-Cell--drug therapy<br/>Patient Selection<br/>Piperidines<br/>Protein Kinase Inhibitors--pharmacology<br/>Proto-Oncogene Proteins c-bcl-2--antagonists & inhibitors<br/>Pyrazoles--pharmacology<br/>Pyrimidines--pharmacology<br/>Sulfonamides--pharmacology